Home Healthcare IT Drug Discovery Market Size, Share and Trends by 2033

Drug Discovery Market Size, Share & Trends Analysis Report By Drug Type (Small Molecule Drugs, Biologic Drugs), By Technology (High Throughput Screening, Pharmacogenomics, Combinatorial Chemistry, Nanotechnology, Others), By End-user (Pharmaceutical Companies, Contract Research Organizations, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI2543DR
Last Updated : Sep 26, 2024
Author : Straits Research
Starting From
USD 2300
Buy Now

Table Of Content

  1. Executive Summary

    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends

    1. Global Drug Discovery Market Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Small Molecule Drugs
        1. By Value
      3. Biologic Drugs
        1. By Value
    3. By Technology 
      1. Introduction
        1. Technology  By Value
      2. High-Throughput Screening (HTS)
        1. By Value
      3. Bioinformatics & In-Silico Modelling
        1. By Value
      4. Computational Drug Discovery & Drug Design
        1. By Value
      5. Nanotechnology
        1. By Value
      6. Others
        1. By Value
    4. By End-user
      1. Introduction
        1. End-user By Value
      2. Pharmaceutical Companies
        1. By Value
      3. Contract Research Organizations
        1. By Value
      4. Others
        1. By Value
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Small Molecule Drugs
        1. By Value
      3. Biologic Drugs
        1. By Value
    3. By Technology 
      1. Introduction
        1. Technology  By Value
      2. High-Throughput Screening (HTS)
        1. By Value
      3. Bioinformatics & In-Silico Modelling
        1. By Value
      4. Computational Drug Discovery & Drug Design
        1. By Value
      5. Nanotechnology
        1. By Value
      6. Others
        1. By Value
    4. By End-user
      1. Introduction
        1. End-user By Value
      2. Pharmaceutical Companies
        1. By Value
      3. Contract Research Organizations
        1. By Value
      4. Others
        1. By Value
    5. U.S.
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Small Molecule Drugs
          1. By Value
        3. Biologic Drugs
          1. By Value
      2. By Technology 
        1. Introduction
          1. Technology  By Value
        2. High-Throughput Screening (HTS)
          1. By Value
        3. Bioinformatics & In-Silico Modelling
          1. By Value
        4. Computational Drug Discovery & Drug Design
          1. By Value
        5. Nanotechnology
          1. By Value
        6. Others
          1. By Value
      3. By End-user
        1. Introduction
          1. End-user By Value
        2. Pharmaceutical Companies
          1. By Value
        3. Contract Research Organizations
          1. By Value
        4. Others
          1. By Value
    6. Canada
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Small Molecule Drugs
        1. By Value
      3. Biologic Drugs
        1. By Value
    3. By Technology 
      1. Introduction
        1. Technology  By Value
      2. High-Throughput Screening (HTS)
        1. By Value
      3. Bioinformatics & In-Silico Modelling
        1. By Value
      4. Computational Drug Discovery & Drug Design
        1. By Value
      5. Nanotechnology
        1. By Value
      6. Others
        1. By Value
    4. By End-user
      1. Introduction
        1. End-user By Value
      2. Pharmaceutical Companies
        1. By Value
      3. Contract Research Organizations
        1. By Value
      4. Others
        1. By Value
    5. U.K.
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Small Molecule Drugs
          1. By Value
        3. Biologic Drugs
          1. By Value
      2. By Technology 
        1. Introduction
          1. Technology  By Value
        2. High-Throughput Screening (HTS)
          1. By Value
        3. Bioinformatics & In-Silico Modelling
          1. By Value
        4. Computational Drug Discovery & Drug Design
          1. By Value
        5. Nanotechnology
          1. By Value
        6. Others
          1. By Value
      3. By End-user
        1. Introduction
          1. End-user By Value
        2. Pharmaceutical Companies
          1. By Value
        3. Contract Research Organizations
          1. By Value
        4. Others
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Small Molecule Drugs
        1. By Value
      3. Biologic Drugs
        1. By Value
    3. By Technology 
      1. Introduction
        1. Technology  By Value
      2. High-Throughput Screening (HTS)
        1. By Value
      3. Bioinformatics & In-Silico Modelling
        1. By Value
      4. Computational Drug Discovery & Drug Design
        1. By Value
      5. Nanotechnology
        1. By Value
      6. Others
        1. By Value
    4. By End-user
      1. Introduction
        1. End-user By Value
      2. Pharmaceutical Companies
        1. By Value
      3. Contract Research Organizations
        1. By Value
      4. Others
        1. By Value
    5. China
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Small Molecule Drugs
          1. By Value
        3. Biologic Drugs
          1. By Value
      2. By Technology 
        1. Introduction
          1. Technology  By Value
        2. High-Throughput Screening (HTS)
          1. By Value
        3. Bioinformatics & In-Silico Modelling
          1. By Value
        4. Computational Drug Discovery & Drug Design
          1. By Value
        5. Nanotechnology
          1. By Value
        6. Others
          1. By Value
      3. By End-user
        1. Introduction
          1. End-user By Value
        2. Pharmaceutical Companies
          1. By Value
        3. Contract Research Organizations
          1. By Value
        4. Others
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Small Molecule Drugs
        1. By Value
      3. Biologic Drugs
        1. By Value
    3. By Technology 
      1. Introduction
        1. Technology  By Value
      2. High-Throughput Screening (HTS)
        1. By Value
      3. Bioinformatics & In-Silico Modelling
        1. By Value
      4. Computational Drug Discovery & Drug Design
        1. By Value
      5. Nanotechnology
        1. By Value
      6. Others
        1. By Value
    4. By End-user
      1. Introduction
        1. End-user By Value
      2. Pharmaceutical Companies
        1. By Value
      3. Contract Research Organizations
        1. By Value
      4. Others
        1. By Value
    5. UAE
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Small Molecule Drugs
          1. By Value
        3. Biologic Drugs
          1. By Value
      2. By Technology 
        1. Introduction
          1. Technology  By Value
        2. High-Throughput Screening (HTS)
          1. By Value
        3. Bioinformatics & In-Silico Modelling
          1. By Value
        4. Computational Drug Discovery & Drug Design
          1. By Value
        5. Nanotechnology
          1. By Value
        6. Others
          1. By Value
      3. By End-user
        1. Introduction
          1. End-user By Value
        2. Pharmaceutical Companies
          1. By Value
        3. Contract Research Organizations
          1. By Value
        4. Others
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Small Molecule Drugs
        1. By Value
      3. Biologic Drugs
        1. By Value
    3. By Technology 
      1. Introduction
        1. Technology  By Value
      2. High-Throughput Screening (HTS)
        1. By Value
      3. Bioinformatics & In-Silico Modelling
        1. By Value
      4. Computational Drug Discovery & Drug Design
        1. By Value
      5. Nanotechnology
        1. By Value
      6. Others
        1. By Value
    4. By End-user
      1. Introduction
        1. End-user By Value
      2. Pharmaceutical Companies
        1. By Value
      3. Contract Research Organizations
        1. By Value
      4. Others
        1. By Value
    5. Brazil
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Small Molecule Drugs
          1. By Value
        3. Biologic Drugs
          1. By Value
      2. By Technology 
        1. Introduction
          1. Technology  By Value
        2. High-Throughput Screening (HTS)
          1. By Value
        3. Bioinformatics & In-Silico Modelling
          1. By Value
        4. Computational Drug Discovery & Drug Design
          1. By Value
        5. Nanotechnology
          1. By Value
        6. Others
          1. By Value
      3. By End-user
        1. Introduction
          1. End-user By Value
        2. Pharmaceutical Companies
          1. By Value
        3. Contract Research Organizations
          1. By Value
        4. Others
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Drug Discovery Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Pfizer Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. GlaxoSmithKline PLC
    3. Merck and Co. Inc.
    4. Agilent Technologies Inc.
    5. Eli Lilly and Company
    6. Hoffmann-La Roche Ltd
    7. Bayer AG
    8. Abbott Laboratories Inc.
    9. Shimadzu Corp
    10. AstraZeneca
    11. Sanofi
    12. Polpharma Biologics Group
    13. Novartis AG
    14. Takeda Pharmaceutical Company Limited.
    15. Teva Pharmaceutical Industries Ltd.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Drug Discovery Outsourcing Market Size The global drug discovery outsourcing market size was valued at USD 3.29 billion in 2021 and is projected to reach an expected value of USD 6.37 billion by 2030 at a CAGR of 7.6% o
Buy Now
Global Report
The Global Drug Discovery Service Market size was valued at USD 9649.12 million in 2019 and is expected to grow at 14.0% CAGR during the forecast period. Drug discovery is the process of designing a new drug by employing various methods such as mole
Buy Now
Global Report
The global in-silico drug discovery market size was valued at USD 2.38 billion in 2021 and is projected to reach USD 5.86 billion by 2030 at a CAGR of 10.45% from 2022 to 2030. In silico, also known as computer-aided drug design, is a method in whic
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report


We are featured on :